—A new analysis took a 2-prong approach to assessing risk factors for wet age-related macular degeneration: a systematic review of the literature, coupled with a study of decades’ worth of data from ...

According to Liu, his preferred option is faricimab, a fairly new agent that was FDA-approved for wet AMD in 2022. The drug ...

EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for ...

In this video, David A. Eichenbaum, MD, FASRS, discusses late-stage wet age-related macular degeneration assets presented at the American Academy of Ophthalmology meeting.Eichenbaum noted that ...

A new analysis took a 2-prong approach to assessing risk factors for wet age-related macular degeneration: a systematic review of the literature, coupled with a study of decades’ worth of data from ...

In this video from the American Academy of Ophthalmology meeting, Esther M. Bowie, MD, discusses what is “new and exciting” in wet age-related macular degeneration.Tyrosine kinase inhibitors being ...

Q3 2025 Management View Jay Duker, President and CEO, described the quarter as one of “tremendous progress” and highlighted “our momentum underscores our confidence in the differentiated clinical ...

Clearside Biomedical, Inc. announced on March 20, 2025, that it presented findings on its lead clinical program, CLS-AX, a suprachoroidal injectable suspension of axitinib, at the 2025 Wet AMD & ...

4D Molecular Therapeutics announced an acceleration in the timeline for its 4FRONT-1 Phase 3 trial data readout of the 4D-150 treatment for wet age-related macular degeneration (AMD), now expected in ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS ...

We’re excited to present a review of our robust data package at OIS, highlighting our momentum toward advancing this innovation into clinical evaluation.” About VLTR-559 VLTR-559 is a long-acting anti ...

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.